PET tracers for somatostatin receptor imaging of neuroendocrine tumors: Current status and review of the literature

Future Oncology

Volumn 10, Issue 14, 2014, Pages 2259-2277

  Johnbeck, Camilla Bardram ^a   Knigge, Ulrich ^b   Kjær, Andreas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

Author keywords

18F DOPA; 64Cu DOTATATE; 68Ga DOTANOC; 68Ga DOTATATE; 68Ga DOTATOC; cancer; molecular imaging; neuroendocrine tumors; PET imaging; somatostatin receptor imaging

Indexed keywords

COPPER 64; FLUORODEOXYGLUCOSE F 18; SOMATOSTATIN RECEPTOR; TETRAXETAN L NAL3 OCTREOTIDE GA 68; TETRAXETAN OCTREOTATE[3 TYROSINE] GA 68; TETRAXETAN OCTREOTIDE[3 TYROSINE] GA 68; TRACER; UNCLASSIFIED DRUG; RADIOPHARMACEUTICAL AGENT;

BONE METASTASIS; CANCER OF UNKNOWN PRIMARY SITE; CLINICAL DECISION MAKING; DOSIMETRY; GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR; HUMAN; IN VITRO STUDY; LIVER METASTASIS; MOLECULAR IMAGING; NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; REVIEW; TASK PERFORMANCE; CHEMISTRY; DIAGNOSTIC USE; META ANALYSIS; METABOLISM; PATHOLOGY; PROCEDURES; RADIOMETRY; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

HUMANS; NEUROENDOCRINE TUMORS; POSITRON-EMISSION TOMOGRAPHY; RADIOMETRY; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 84916595810     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.14.139     Document Type: Review

References (102)

1. Yao JC, Hassan M, Phan A et al. One hundred years after 'carcinoid': epidemiology of and prognostic factors for neuroendocrine tumors in 35, 825 cases in the United States. J. Clin. Oncol. 26(18), 3063-3072 (2008).
2. Fraenkel M, Kim MK, Faggiano A, de Herder W W, Valk GD. Incidence of gastroenteropancreatic neuroendocrine tumours: a systematic review of the literature. Endocr. Relat. Cancer 21(3), R152-R163 (2014).
3. Rindi G, Arnold R, Bosman FT et al. Nomenclature and classifcation of neuroendocrine neoplasms of the digestive system. In: WHO Classifcation of Tumours of the Digestive System (4th Edition). Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds). International Agency for Research on Cancer (IARC), France, 13-14 (2010).
4. Klöppel G. Classifcation and pathology of gastroenteropancreatic neuroendocrine neoplasms. Endocr. Relat. Cancer 18(Suppl. 1), S1-S16 (2011).
5. Rindi G, Klöppel G, Alhman H et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 449(4), 395-401 (2006).
6. Rindi G, Klöppel G, Couvelard A et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 451(4), 757-762 (2007).
7. Travis WD. The concept of pulmonary neuroendocrine tumour. In: Pathology and Genetics of Tumours of the Lung, Pleura, Thymus and Heart. World Health Organization Classifcation of Tumours. Travis WD, Brambilla E, Müller-Hermelink HK, Harris CC (Eds). International Agency for Research on Cancer (IARC), France, 19-20 (2004).
8. Rindi G, Klersy C, Inzani F et al. Grading the neuroendocrine tumors of the lung: an evidence-based proposal. Endocr. Relat. Cancer 21(1), 1-16 (2014).
9. Eriksson B, Oberg K. Summing up 15 years of somatostatin analog therapy in neuroendocrine tumors: future outlook. Ann. Oncol. 10(Suppl. 2), S31-S38 (1999).
10. Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment. Pharmacol. Ther. 31(2), 169-188 (2010).
11. Rinke A, Müller H-H, Schade-Brittinger C et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J. Clin. Oncol. 27(28), 4656-4663 (2009).
12. Hoyer D, Bell GI, Berelowitz M et al. Classifcation and nomenclature of somatostatin receptors. Trends Pharmacol. Sci. 16(3), 86-88 (1995).
13. Kubota A, Yamada Y, Kagimoto S et al. Identifcation of somatostatin receptor subtypes and an implication for the effcacy of somatostatin analogue SMS 201-995 in treatment of human endocrine tumors. J. Clin. Invest. 93(3), 1321-1325 (1994).
14. Reubi JC. Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 80(Suppl. 1), 51-56 (2004).
15. Binderup T, Knigge U, Mellon Mogensen A, Palnaes Hansen C, Kjær A. Quantitative gene expression of somatostatin receptors and noradrenaline transporter underlying scintigraphic results in patients with neuroendocrine tumors. Neuroendocrinology 87(4), 223-232 (2008).
16. Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur. J. Nucl. Med. 28(7), 836-846 (2001).
17. Modlin IM, Oberg K, Chung DC et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 9(1), 61-72 (2008).
18. Bauer W, Briner U, Doepfner W et al. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci. 31(11), 1133-1140 (1982).
19. Krenning EP, Bakker WH, Breeman WA et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet 1(8632), 242-244 (1989).
20. 123I-Ty r 3]-octreotide: the Rotterdam experience with more than 1000 patients. Eur. J. Nucl. Med. 20(8), 716-731 (1993).
21. 68Ga-DOTANOC PET: a promising prognostic tool in neuroendocrine tumors. J. Nucl. Med. 51(3), 353-359 (2010).
22. ®). Mol. Imaging Biol. 13(3), 583-593 (2011).
23. 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 34(10), 1617-1626 (2007).
24. Hofman MS, Kong G, Neels OC, Eu P, Hong E, Hicks RJ. High management impact of Ga-68 DOTATATE (GaTate) PET/CT for imaging neuroendocrine and other somatostatin expressing tumours. J. Med. Imaging Radiat. Oncol. 56(1), 40-47 (2012).
25. 68Ga-DOTATOC: preliminary data. Eur. J. Nucl. Med. 28(12), 1751-1757 (2001).
26. 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: comparison with somatostatin receptor scintigraphy and CT. J. Nucl. Med. 48(4), 508-518 (2007).
27. 111In-DTPA-octreotide scintigraphy. J. Nucl. Med. 51(6), 875-882 (2010).
28. 68Ga-DOTATOC PET/CT for staging enteropancreatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 39(1), 72-82 (2012).
29. Al-Nahhas A, Win Z, Szyszko T et al. Gallium-68 PET: a new frontier in receptor cancer Imaging Anticancer Res. 27(6B), 4087-4094 (2007).
30. Pavel M, Baudin E, Couvelard A et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 95(2), 157-176 (2012).
31. Pape U-F, Perren A, Niederle B et al. ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas. Neuroendocrinology 95(2), 135-156 (2012).
32. Falconi M, Bartsch DK, Eriksson B et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. Neuroendocrinology 95(2), 120-134 (2012).
33. Caplin M, Sundin A, Nillson O et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: colorectal neuroendocrine neoplasms. Neuroendocrinology 95(2), 88-97 (2012).
34. Jensen RT, Cadiot G, Brandi ML et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology 95(2), 98-119 (2012).
35. Reubi JC, Schär JC, Waser B et al. Affnity profles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27(3), 273-282 (2000).
36. Reubi JC, Erchegyi J, Cescato R, Waser B, Rivier JE. Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog. Eur. J. Nucl. Med. Mol. Imaging 37(8), 1551-1558 (2010).
37. Waser B, Tamma M-L, Cescato R, Maecke HR, Reubi JC. Highly effcient in vivo agonist-induced internalization of sst2 receptors in somatostatin target tissues. J. Nucl. Med. 50(6), 936-941 (2009).
38. Cescato R, Schulz S, Waser B et al Internalization of sst2, sst3, and sst5 receptors: effects of somatostatin agonists and antagonists. J. Nucl. Med. 47(3), 502-511 (2006).
39. Ginj. M, Zhang H, Waser B et al. Radiolabeled somatostatin receptor antagonists are preferable to agonists for in vivo peptide receptor targeting of tumors. Proc. Natl Acad. Sci. USA 103(44), 16436-16441 (2006).
40. Reubi JC. Old and new peptide receptor targets in cancer: future directions. Recent Results Cancer Res. 194, 567-576 (2013).
41. Wild D, Fani M, Behe M et al. First clinical evidence that imaging with somatostatin receptor antagonists is feasible. J. Nucl. Med. 52(9), 1412-1417 (2011).
42. 64Cu-TETA-octreotide as a PET imaging agent for patients with neuroendocrine tumors. J. Nucl. Med. 42(2), 213-221 (2001).
43. 64Cu-DOTATATE: frst-in-humans study. J. Nucl. Med. 53(8), 1207-1215 (2012).
44. Antunes P, Gin J. M, Zhang H et al. Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals? Eur. J. Nucl. Med. Mol. Imaging 34(7), 982-993 (2007).
45. 111In]DTPA-octreotide. J. Nucl. Med. 47(4), 566-573 (2006).
46. Prieto E, Domínguez-Prado I, García-Velloso MJ, Peñuelas I, Richter JÁ, Martí-Climent JM. Impact of time-of-fight and point-spread-function in SUV quantifcation for oncological PET Clin. Nucl. Med. 38(2), 103-109 (2013).
47. 68Ga-DOTA-TOC uptake in neuroendocrine tumour and healthy tissue: differentiation of physiological uptake and pathological processes in PET/CT Eur. J. Nucl. Med. Mol. Imaging 40(12), 1800-1808. (2013).
48. Prasad V, Baum RP. Biodistribution of the Ga-68 labeled somatostatin analogue DOTA-NOC in patients with neuroendocrine tumors: characterization of uptake in normal organs and tumor lesions. Q. J. Nucl. Med. Mol. Imaging 54(1), 61-67 (2010).
49. 68Ga-DOTA-TATE PET/CT Clin. Nucl. Med. 37(11), 1052-1057 (2012).
50. Krausz Y, Rubinstein R, Appelbaum L et al. Ga-68 DOTA-NOC uptake in the pancreas: pathological and physiological patterns. Clin. Nucl. Med. 37(1), 57-62 (2012).
51. Reubi JC, Waser B. Concomitant expression of several peptide receptors in neuroendocrine tumours: molecular basis for in vivo multireceptor tumour targeting. Eur. J. Nucl. Med. Mol. Imaging 30(5), 781-793 (2003).
52. 90Y-DOTATOC therapy. Eur. J. Nucl. Med. Mol. Imaging 33(4), 460-466 (2006).
53. 68Ga-DOTA-Tyr3-octreotide PET in comparison to CT and bone scintigraphy J. Nucl. Med. 50(8), 1214-1221 (2009).
54. Versari A, Camellini L, Carlinfante G et al. Ga-68 DOTATOC PET, endoscopic ultrasonography, and multidetector CT in the diagnosis of duodenopancreatic neuroendocrine tumors: a single-centre retrospective study. Clin. Nucl. Med. 35(5), 321-328 (2010).
55. Stats calculator. http://ktclearinghouse.ca/cebm/practise/ca/calculators/statscalc
56. 18F-FDG. Cancer 112(11), 2447-2455 (2008).
57. 18F-FDG PET/CT in pulmonary neuroendocrine tumors. J. Nucl. Med. 50(12), 1927-1932 (2009).
58. 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 36(5), 765-770 (2009).
59. 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 39(8), 1271-1277 (2012).
60. 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J. Nucl. Med. 54(3), 364-372 (2013).
61. 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 35(8), 1431-1438 (2008).
62. 68Ga-DOTA-NOC: a new PET tracer for evaluating patients with bronchial carcinoid. Nucl. Med. Commun. 30(4), 281-286 (2009).
63. 68Ga-DOTA-NOC PET/CT in comparison with CT for the detection of bone metastasis in patients with neuroendocrine tumours. Eur. J. Nucl. Med. Mol. Imaging 37(4), 722-727 (2010).
64. Naswa N, Sharma P, Kumar A et al Gallium-68-DOTA-NOC PET/CT of patients with gastroenteropancreatic neuroendocrine tumors: a prospective single-center study. Am. J. Roentgenol. 197(5), 1221-1228 (2011).
65. 68Ga-DOTANOC in gastrinoma patients with negative or equivocal CT fndings. Abdom. Imaging 38(3), 552-560 (2013).
66. 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET. Eur. J. Nucl. Med. Mol. Imaging 39(Suppl. 1), S52-S60 (2012).
67. 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J. Nucl. Med. 52(12), 1864-1870 (2011).
68. 68Ga-DOTA (0)-lanreotide. Eur. J. Nucl. Med. Mol. Imaging 40(3), 364-371. (2013).
69. Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours. Nucl. Med. Commun. 34(8), 727-732 (2013).
70. Treglia G, Castaldi P, Rindi G, Giordano A, Rufni V. Diagnostic performance of gallium-68 somatostatin receptor PET and PET/CT in patients with thoracic and gastroenteropancreatic neuroendocrine tumours: a meta-analysis. Endocrine 42(1), 80-87 (2012).
71. 68Ga-DOTATOC PET/CT in the evaluation of primary pulmonary carcinoids. Korean J. Intern. Med. 25(4), 386-391 (2010).
72. Panzuto F, Nasoni S, Falconi M et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr. Relat. Cancer 12(4), 1083-1092 (2005).
73. Gupta S, Johnson MM, Murthy R et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer 104(8), 1590-1602 (2005).
74. 68Ga-DOTA-NOC receptor PET/CT. Eur. J. Nucl. Med. Mol. Imaging 37(1), 67-77 (2010).
75. 68Ga-DOTANOC PET/CT in patients with carcinoma of unknown primary of neuroendocrine origin. Clin. Nucl. Med. 37(3), 245-251 (2012).
76. 68Ga-DOTATATE PET/CT in the detection of neuroendocrine tumours. Nucl. Med. Rev. Cent. East Eur. 14(1), 16-20 (2011).
77. 68Ga-DOTA-NOC PET. Biomed. Pharmacother. 62(10), 667-671 (2008).
78. 68Ga-DOTATOC positron emission tomography/computed tomography on the multimodal management of patients with neuroendocrine tumors. Ann. Surg. 252(5), 850-856 (2010).
79. Froeling V, Elgeti F, Maurer MH et al. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia. Ann. Nucl. Med. 26(9), 738-743 (2012).
80. 68Ga-DOTANOC PET/CT clinical impact in patients with neuroendocrine tumors. J. Nucl. Med. 51(5), 669-673 (2010).
81. 68Ga-DOTANOC: biodistribution and dosimetry in patients affected by neuroendocrine tumors. Eur. J. Nucl. Med. Mol. Imaging 35(1), 72-79 (2008).
82. 68Ga-DOTATOC PET/CT examinations]. Nuklearmedizin 48(5), 201-207 (2009).
83. 68Ga-DOTATATE. J. Nucl. Med. 54(6), 855-860. (2013).
84. 68Ga-DOTANOC uptake in the pancreatic head in a large series of extrapancreatic NET patients studied with sequential PET/CT. J. Nucl. Med. 52(6), 886-890 (2011).
85. 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy. Mol. Imaging 9(6), 351-358 (2010).
86. 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake. J. Nucl. Med. 40(5), 762-767 (1999).
87. 68Ga-DOTATOC PET/CT of neuroendocrine tumors: spotlight on the CT phases of a triple-phase protocol. J. Nucl. Med. 52(5), 697-704 (2011).
88. 68Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen? Eur. Radiol. 22(4), 938-946 (2012).
89. Schreiter NF, Nogami M, Steffen I et al. Evaluation of the potential of PET-MRI fusion for detection of liver metastases in patients with neuroendocrine tumours. Eur. Radiol. 22(2), 458-467 (2012).
90. Giesel FL, Kratochwil C, Mehndiratta A et al. Comparison of neuroendocrine tumor detection and characterization using DOTATOC-PET in correlation with contrast enhanced CT and delayed contrast enhanced MRI. Eur. J. Radiol. 81(10), 2820-2825 (2012).
91. 68Ga-DOTATOC positron emission tomography/magnetic resonance in comparison with positron emission tomography/computed tomography in patients with neuroendocrine tumors. Invest. Radiol. 48(5), 263-272 (2013).
92. Kjær A, Loft A, Law I et al. PET/MRI in cancer patients: frst experiences and vision from Copenhagen. MAGMA 26(1), 37-47 (2013).
93. 68Ga-DOTATOC PET/MRI in patients with gastroenteropancreatic neuroendocrine tumors: initial results. Invest. Radiol. 48(5), 273-279 (2013).
94. 18F-fuoro-L-dihydroxyphenylalanine positron emission tomography in neuroendocrine tumor patients. Q. J. Nucl. Med. Mol. Imaging 54(1), 68-75 (2010).
95. 18F-fuorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin. Cancer Res. 16(3), 978-985 (2010).
96. 18F-FDG PET. J. Nucl. Med. 51(5), 704-712 (2010).
97. Oh S, Prasad V, Lee DS, Baum RP. Effect of peptide receptor radionuclide therapy on somatostatin receptor status and glucose metabolism in neuroendocrine tumors: intraindividual comparison of Ga-68 DOTANOC PET/CT and F-18 FDG PET/C T. Int J. Mol. Imaging 2011, 524130 (2011).
98. Wild D, Mäcke H, Christ E, Gloor B, Reubi JC. Glucagon-like peptide 1-receptor scans to localize occult insulinomas. N. Engl. J. Med. 359(7), 766-768 (2008).
99. Christ E, Wild D, Forrer F et al. Glucagon-like peptide-1 receptor imaging for localization of insulinomas. J. Clin. Endocrinol. Metab. 94(11), 4398-4405 (2009).
100. Eriksson O, Velikyan I, Selvaraju RK et al. Detection of metastatic insulinoma by positron emission tomography with [(68)Ga] exendin-4-a case report. J. Clin. Endocrinol. Metab. 99 (5), 1519-1524 (2014).
101. Wild D, Theodoraki A, Kurzawinski TR et al. 'Running on empty'. Eur. J. Nucl. Med. Mol. Imaging 37(7), 1439-1440 (2010).
102. Wild D, Christ E, Caplin ME et al. Glucagon-like peptide-1 versus somatostatin receptor targeting reveals 2 distinct forms of malignant insulinomas. J. Nucl. Med. 52(7), 1073-1078 (2011).